Edesa Biotech Announces Pricing of $25.0 Million Public Offering
Rhea-AI Summary
Edesa Biotech (Nasdaq: EDSA) priced an underwritten public offering of (i) 3,870,500 common shares with accompanying common share warrants and (ii) pre-funded warrants to purchase up to 675,000 common shares, each paired with a common share warrant. Each common share unit is priced at $5.50, and each pre-funded warrant unit at $5.4999, reflecting a pre-funded warrant exercise price of $0.0001 per share.
The common share warrants have an exercise price of $7.50 per share, are immediately exercisable, and will expire on the earlier of 18 months from issuance or 30 days after Edesa publicly announces Phase 2 vitiligo topline data for EB06. Gross proceeds are expected to be approximately $25.0 million before fees. The company granted underwriters a 30-day option to buy up to an additional 681,825 common shares and accompanying warrants. Closing is expected on or about August 21, 2026, with Guggenheim Securities as sole book-runner. Edesa plans to use net proceeds for general corporate purposes, including working capital, capital expenditures, and R&D and manufacturing expenses.
Positive
- Underwritten public offering expected to raise approximately $25.0 million in gross proceeds
- Base deal structured around 3,870,500 common shares plus pre-funded warrants for up to 675,000 shares
- Common share warrants immediately exercisable at $7.50 per share with defined clinical data-linked expiry
- Additional capital flexibility via 30-day underwriter option for up to 681,825 extra common shares and warrants
Negative
- Equity financing introduces dilution through issuance of 3,870,500 new common shares, before any pre-funded warrant exercises
- Common share warrants issued for up to 4,545,500 shares, plus up to 681,825 more if the underwriters’ option is exercised, adding future dilution overhang
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 13 | Fiscal results | Negative | -1.5% | Higher quarterly losses and increased operating expenses accompanied fiscal third-quarter updates. |
| Jun 11 | Private placement | Negative | +8.4% | A $3.5 million private placement led by the CEO and healthcare-focused investors. |
| Jun 05 | Clinical data | Positive | -23.0% | Exploratory paridiprubart analyses showed lower mortality and MAKE30 incidence. |
| May 19 | Clinical presentation | Neutral | +32.8% | The company announced an upcoming presentation of exploratory Phase 3 kidney injury data. |
| May 14 | Fiscal results | Negative | -10.7% | Quarterly and year-to-date net losses increased alongside higher operating expenses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed, with negative reactions following some positive clinical updates and a positive reaction following the prior private placement.
Key Terms
underwritten public offering financial
pre-funded warrants financial
shelf registration statement regulatory
Form S-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded warrants to purchase up to 675,000 common shares and accompanying common share warrants to purchase an aggregate of 675,000 common shares, at an exercise price of
All common shares, pre-funded warrants and accompanying common share warrants are being offered by Edesa. The offering is expected to close on or about August 21, 2026, subject to the satisfaction of customary closing conditions.
Guggenheim Securities is acting as the sole book-running manager for the offering.
Edesa intends to use the net proceeds from the offering for general corporate purposes, which may include working capital, capital expenditures and research and development and manufacturing expenses.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-288966), including a base prospectus, that was declared effective by the Securities and Exchange Commission (“SEC”) on September 9, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and a final prospectus supplement with the final terms of the offering will be filed with the SEC and will be available for free on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “will,” “would,” “could,” “should,” “might,” “potential,” or “continue” and variations or similar expressions, including statements regarding the Company’s expectations regarding the satisfaction of customary closing conditions related to the offering, the expected closing of the offering and the anticipated use of proceeds therefrom. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: market and other conditions, those relating to the anticipated use of proceeds, the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa’s operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa’s product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa’s ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the Company’s ability to control or predict. For a discussion of further risks and uncertainties related to Edesa’s business, please refer to Edesa’s reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact:
Gary Koppenjan
Edesa Biotech, Inc.
investors@edesabiotech.com
